Acetic acid derivatives of 3,4-dihydro-2 H-1,2,4-benzothiadiazine 1,1-dioxide as a novel class of potent aldose reductase inhibitors

Journal of Medicinal Chemistry

Volumn 53, Issue 23, 2010, Pages 8330-8344

  Chen, Xin ^a   Zhu, Changjin ^a   Guo, Fan ^a   Qiu, Xiaowei ^a   Yang, Yanchun ^a   Zhang, Shuzhen ^a   He, Minlan ^a   Parveen, Shagufta ^a   Jing, Chaojun ^a   Li, Yan ^a   Ma, Bing ^a  

^a BEIJING INSTITUTE OF TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID DERIVATIVE; ALDOSE REDUCTASE INHIBITOR; BENZOTHIADIAZINE DERIVATIVE; HALOGEN; SORBITOL; STREPTOZOCIN;

ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ACTIVITY; DRUG SYNTHESIS; HUMAN; IC 50; IN VITRO STUDY; MOLECULAR DOCKING; NONHUMAN; RAT; SCIATIC NERVE; STRUCTURE ACTIVITY RELATION;

ACETIC ACID; ALDEHYDE REDUCTASE; ANIMALS; BENZOTHIADIAZINES; CYCLIC S-OXIDES; DIABETES MELLITUS, EXPERIMENTAL; ENZYME INHIBITORS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78649855244     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm100962a     Document Type: Article

References (55)

1. World Health Organization. Disease Action Now Booklet. http://www.who/diabetes/pubs/pdf/ndfs.pdf (accessed Feb 6, 2010).
2. Yang, W.; Lu, J.; Weng, J.; Jia, W.; Ji, L.; Xiao, J.; Shan, Z.; Liu, J.; Tian, H.; Ji, Q.; Zhu, D.; Ge, J.; Lin, L.; Chen, L.; Guo, X.; Zhao, Z.; Li, Q.; Zhou, Z.; Shan, G.; He, J. Prevalence of diabetes among men and women in China N. Engl. J. Med. 2010, 362, 1090-1101
3. Nathan, D. M. Long-term complications of diabetes mellitus N. Engl. J. Med. 1988, 318, 1315-1321
4. Alexiou, P.; Pegklidou, K.; Chatzopoulou, M.; Nicolaou, I.; Demopoulos, V. J. Aldose reductase enzyme and its implication to major health problems of the 21st century Curr. Med. Chem. 2009, 16, 734-752
5. Hers, H. G. The mechanism of the transformation of glucose in fructose in the seminal vesicles Biochim. Biophys. Acta 1956, 22, 202-203
6. van Heyningen, R. Formation of polyols by the lens of the rat with "sugar" cataract Nature (London) 1959, 184, 194-195
7. Gabbay, K. H.; Merola, L. O.; Field, R. A. Sorbitol pathway: presence in nerve and cord with substrate accumulation in diabetes Science 1966, 151, 209-210
8. Kinoshita, J. H.; Nishimura, C. The involvement of aldose reductase in diabetic complications Diabetes Metab. Rev. 1988, 4, 323-337
9. Yabe-Nishimura, C. Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications Pharmacol. Rev. 1998, 50, 21-33
10. Chung, S. S.; Chung, S. K. Genetic analysis of aldose reductase in diabetic complications Curr. Med. Chem. 2003, 10, 1375-1387
11. Kador, P. F.; Kinoshita, J. H.; Sharpless, N. E. Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications J. Med. Chem. 1985, 28, 841-849
12. Hayman, S.; Kinoshita, J. H. Isolation and properties of lens aldose reductase J. Biol. Chem. 1965, 240, 877-882
13. Dvornik, D.; Simard-Duquesne, N.; Keami, M.; Sestanj, K. Polyol accumulation in galactosemic and diabetic rats: control by an aldose reductase inhaibitor Science 1973, 182, 1146-1147
14. Sestanj, K.; Bellini, F.; Fung, S.; Abraham, N.; Treasurywala, A.; Humber, L.; Simard-Duquesne, N.; Dvornik, D. N -[5-(Trifluoromethyl)-6-methoxy- 1-naphthalenyl]thioxomethyl]- N -methylglycine (Tolrestat), a potent, orally active aldose reductase inhibitor J. Med. Chem. 1984, 27, 255-256
15. Kikkawa, R.; Hatanaka, I.; Yasuda, H.; Kobayashi, N.; Shigeta, Y.; Terashima, H.; Morimura, T.; Tsuboshima, M. Effect of a new aldose reductase inhibitor, (E)-3-carboxymethyl-5-[(2 E)-methyl-3-phenylpropenylidene]rhodanine (ONO-2235) on peripheral nerve disorders in streptozotocin-diabetic rats Diabetologia 1983, 24, 290-292
16. Mylari, B. L.; Larson, E. R.; Beyer, T. A.; Zembrowski, W. J.; Aldinger, C. E.; Dee, M. F.; Siegel, T. W.; Singleton, D. H. Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2- benzothiazolyl]methyl]-1-phthalazineacetic acid (zopolrestat) and congeners J. Med. Chem. 1991, 34, 108-122
17. Ao, S.; Shingu, Y.; Kikuchi, C.; Takano, Y.; Nomura, K.; Fujiwara, T.; Ohkubo, Y.; Notsu, Y.; Yamaguchi, I. Characterization of a novel aldose reductase inhibitor, FR74366, and its effects on diabetic cataract and neuropathy in the rat Metabolism 1991, 40, 77-87
18. Stribling, D.; Mirrlees, D. J.; Harrison, H. E.; Earl, D. C. Properties of ICI 128,436, a novel aldose reductase inhibitor, and its effects on diabetic complications in the rat Metabolism 1985, 34, 336-344
19. Van Zandt, M. C.; Jones, M. L.; Gunn, D. E.; Geraci, L. S.; Jones, J. H.; Sawicki, D. R.; Sredy, J.; Jacot, J. L.; DiCioccio, A. T.; Petrova, T.; Mitschler, A.; Podjarny, A. D. Discovery of 3-[(4,5,7-trifluorobenzothiazol-2- yl)methyl]indole- N -acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications J. Med. Chem. 2005, 48, 3141-3152
20. Da Settimo, F.; Primofiore, G.; La Motta, C.; Sartini, S.; Taliani, S.; Simorini, F.; Marini, A. M.; Lavecchia, A.; Novellino, E.; Boldrini, E. Naphtho[1,2- d ]isothiazole acetic acid derivatives as a novel class of selective aldose reductase inhibitors J. Med. Chem. 2005, 48, 6897-6907
21. La Motta, C.; Sartini, S.; Salerno, S.; Simorini, F.; Taliani, S.; Marini, A. M.; Settimo, F. D.; Marinelli, L.; Limongelli, V.; Novellino, E. Acetic acid aldose reductase inhibitors bearing a five-membered heterocyclic core with potent topical activity in a visual impairment rat model J. Med. Chem. 2008, 57, 3182-3193
22. Hamada, Y.; Nakamura, J. Clinical potential of aldose reductase inhibitors in diabetic neuropathy Treat. Endocrinol. 2004, 3, 245-255
23. Costantino, L.; Rastelli, G.; Vianello, P.; Cignarella, G.; Barlocco, D. Diabetes complications and their potential prevention: aldose reductase inhibition and other approaches Med. Res. Rev. 1999, 19, 3-23
24. Fukushi, S.; Merola, L. O.; Kinoshita, J. H. Altering the course of cataracts in diabetic rats Invest. Ophthalmol. Visual Sci. 1980, 19, 313-315
25. Asano, T.; Saito, Y.; Kawakami, M.; Yamada, N. Fidarestat (SNK-860), a potent aldose reductase inhibitor, normalizes the elevated sorbitol accumulation in erythrocytes of diabetic patients J. Diabetes Complications 2002, 16, 133-138
26. Negoro, T.; Murata, M.; Ueda, S.; Fujitani, B.; Kuromiya, M.; Suzuki, K.; Matsumoto, J. Novel, highly potent aldose reductase inhibitors: R -(-)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo[1,2- a ]pyrazine-4-spiro-31-pyrrolidine-1,21,3,51-tetrone (AS-3201) and its congeners J. Med. Chem. 1998, 41, 4118-4129
27. Kurono, M.; Fujii, A.; Murata, M.; Fujitani, B.; Negoro, T. Stereospecific recognition of a spirosuccinimide type aldose reductase inhibitor (AS-3201) by plasma proteins: a significant role of specific binding by serum albumin in the improved potency and stability Biochem. Pharmacol. 2006, 71, 338-353
28. Giannoukakis, N. Drug evaluation: ranirestat, an aldose reductase inhibitor for the potential treatment of diabetic complications Curr. Opin. Invest. Drugs. 2006, 7, 916-923
29. Mylari, B. L.; Armento, S. J.; Beebe, D. A.; Conn, E. L.; Coutcher, J. B.; Dina, M. S.; O'Gorman, M. T.; Linhares, M. C.; Martin, W. H.; Oates, P. J.; Tess, D. A.; Withbroe, G. J.; Zembrowski, W. J. A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran-2-sulfonyl)-2 H -pyridazin-3-one and congeners J. Med. Chem. 2005, 48, 6326-6339
30. La Motta, C.; Sartini, S.; Mugnaini, L.; Simorini, F.; Taliani, S.; Salerno, S.; Marini, A. M.; Settimo, F. D.; Lavecchia, A.; Novellino, E.; Cantore, M.; Failli, P.; Ciuffi, M. Pyrido[1,2- a ]pyrimidin-4-one derivatives as a novel class of selective aldose reductase inhibitors exhibiting antioxidant activity J. Med. Chem. 2007, 50, 4917-4927
31. El-Kabbani, O.; Wilson, D. K.; Petrash, M.; Quiocho, F. A. Structural features of the aldose reductase and aldehyde reductase inhibitor-binding sites Mol. Vision 1998, 4, 19-25
32. Bohren, K. M.; Grimshaw, C. E.; Gabbay, K. H. Catalytic effectiveness of human aldose reductase. Critical role of C terminal domain J. Biol. Chem. 1992, 267, 20965-20970
33. Urzhumtsev, A.; Tete-Favier, F.; Mitscler, A.; Barbanton, J.; Barth, P.; Urzhumgtseva, L.; Biellmann, J. F.; Podjarny, A. D.; Moras, D. A "specificity" pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil Structure 1997, 5, 601-612
34. Barski, O. A.; Gabbay, K. H.; Bohren, K. M. The C-terminal loop of aldehyde reductase determines the substrate and inhibitor specificity Biochemistry 1996, 35, 14276-14280
35. Carper, D. A.; Wistow, G.; Nishimura, C.; Graham, C.; Watanabe, K.; Fujii, Y.; Hayashi, H.; Hayaishi, O. A superfamily of NADPH-dependent reductases in eukaryotes and prokaryotes Exp. Eye Res. 1989, 49, 377-388
36. Feather, M. S.; Flynn, T. G.; Munro, K. A.; Kubiseski, T. J.; Walton, D. J. Catalysis of reduction of carbohydrate 2-oxoaldehydes (osones) by mammalian aldose reductase and aldehyde reductase Biochim. Biophys. Acta 1995, 1244, 10-16
37. Ratliff, D. M.; Van der Jagt, D. J.; Eaton, R. P.; Van der Jagt, D. L. Increased levels of methylglyoxal-metabolizing enzymes in mononuclear and polymorphonuclear cells from insulindependent diabetic patients with diabetic complications: aldose reductase, glyoxalase I, and glyoxalase II-a clinical research center study J. Clin. Endocrinol. Metab. 1996, 81, 488-492
38. Timmemans, P. B. M.; Smith, R. D. In Burger's Medicinal Chemistry and Drug Discovery, 5 th Ed.; Wolf, M. E., Ed.; John Wiley & Sons: New York, 1996; Vol. 2, pp 265 - 321.
39. Longman, S. D.; Hamilton, T. C. Potassium channel activator drugs: mechanism of action, pharmacological properties, and therapeutic potential Med. Res. Rev. 1992, 12, 73-148
40. Buckheit, R. W., Jr.; Fliakas-Boltz, V.; Decker, W. D.; Roberson, J. L.; Pyle, C. A.; White, E. L.; Bowdon, B. J.; McMahon, J. B.; Boyd, M. R.; Bader, J. P.; Nickell, D. G.; Barth, H.; Antonucci, T. K. Biological and biochemical anti-HIV activity of the benzothiadiazine class of nonnucleoside reverse transcriptase inhibitors Antiviral Res. 1994, 25, 43-56
41. Yamada, K. A.; Tang, C. M. Benzothiadiazides inhibit rapid glutamate receptor desensitization and enhance glutamatergic synaptic currents J. Neurosci. 1993, 13, 3904-3915
42. Lestage, P.; Danober, L.; Lockhart, B.; Roger, A.; Lebrun, C.; Robin, J.-L.; Desos, P.; Cordi, A. S18986, positive allosteric modulator of AMPA receptors as a novel cognition enhancer in rodents Res. Pract. Alzheimer's Dis. 2002, 6, 253-259
43. Phillips, D.; Sonnenberg, J.; Arai, A. C.; Vaswani, R.; Krutzik, P. O.; Kleisli, T.; Kessler, M.; Granger, R.; Lynch, G.; Chamberlin, A. R. 5′-Alkyl-benzothiadiazides: a new subgroup of AMPA receptor modulators with improved affinity Bioorg. Med. Chem. 2002, 10, 1229-1248
44. Braghiroli, D.; Puia, G.; Cannazza, G.; Tait, A.; Parenti, C.; Losi, G.; Baraldi, M. Synthesis of 3,4-dihydro-2 H -1,2,4-benzothiadiazine 1,1-dioxide derivatives as potential allosteric modulators of AMPA/kainate receptors J. Med. Chem. 2002, 45, 2355-2357
45. Pirotte, B.; Podona, T.; Diouf, O.; de Tullio, P.; Lebrun, P.; Dupont, L.; Somers, F.; Delarge, J.; Morain, P.; Lestage, P.; Lepagnol, J.; Spedding, M. 4 H -1,2,4-Pyridothiadiazine 1,1-dioxides and 2,3-dihydro-4 H -1,2,4-pyridothiadiazine 1,1-dioxides chemically related to diazoxide and cyclothiazide as powerful positive allosteric modulators of (R / S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid receptors: design, synthesis, pharmacology, and structure-activity relationships J. Med. Chem. 1998, 41, 2946-2959
46. Francotte, P.; de Tullio, P.; Goffin, E.; Dintilhac, G.; Graindorge, E.; Fraikin, P.; Lestage, P.; Danober, L.; Thomas, J.-Y.; Caignard, D.-H.; Pirotte, B. Design, synthesis, and pharmacology of novel 7-substituted3,4-dihydro-2 H -1,2,4-benzothiadiazine 1,1-dioxides as positive allosteric modulators of AMPA receptors J. Med. Chem. 2007, 50, 3153-3157
47. Pyridazinone Compounds. World Patent WO2006066079, June 22, 2006.
48. Suzen, S.; Buyukbingol, E. Recent studies of aldose reductase enzyme inhibition for diabetic complications Curr. Med. Chem. 2003, 10, 1329-1352
49. Wrobel, J.; Millen, J.; Sredy, J.; Dietrich, A.; Gorham, B. J.; Malamas, M.; Kelly, J. M.; Bauman, J. G.; Harrison, M. C.; Jones, L. R.; Guinosso, C.; Sestanj, K. Syntheses of tolrestat analogs containing additional substituents in the ring and their evaluation as aldose reductase inhibitors. Identification of potent, orally active 2- fluoro derivatives J. Med. Chem. 1991, 34, 2504-2520
50. Sotriffer, C. A.; Krämer, O.; Klebe, G. Probing flexibility and "induced-fit" phenomena in aldose reductase by comparative crystal structure analysis and molecular dynamics simulations Proteins 2004, 56, 52-66
51. Urzhumtsev, A.; Tete-Favier, F.; Mitschler, A.; Barbanton, J.; Barth, P.; Urzhumtseva, L.; Biellmann, J. F.; Podjarny, A.; Moras, D. A "specificity" pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil Structure 1997, 5, 601-612
52. Steuber, H.; Zentgraf, M.; Gerlach, C.; Sotriffer, C. A.; Heine, A.; Klebe, G. Expect the unexpected or caveat for drug designers: multiple structure determinations using aldose reductase crystals treated under varying soaking and co-crystallisation conditions J. Mol. Biol. 2006, 363, 174-187
53. Howard, E. I.; Sanishvili, R.; Cachau, R. E.; Mitschler, A.; Chevrier, B.; Barth, P.; Lamour, V.; Van Zandt, M.; Sibley, E.; Bon, C.; Moras, D.; Schneider, T. R.; Joachimiak, A.; Podjarny, A. Ultrahigh resolution drug design i: details of interactions in human aldose reductase-inhibitor complex at 0.66 Å Proteins 2004, 55, 792-804
54. Bergmeyer, H. V.; Gruber, W.; Gutman, I. In Methods of Engymatic Analysis; Bergmeyer, H. V., Ed.; Academic Press: New York, 1974; Vol. 3, pp 1323 - 1330.
55. Murata, M.; Fujitani, B.; Mizuta, H. Synthesis and aldose reductase inhibitory activity of a new series of 5-[[2-(-carboxyalkoxy)aryl]methylene]-4- oxo-2-thioxothiazolidine derivatives Eur. J. Med. Chem. 1999, 34, 1061-1070